GOT1

Across TCGA pan-cancer cohorts, GOT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GOT1 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GOT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GOT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where GOT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.522	0.302	<.001	77	view →
LUAD	OS	Median	All	0.548	0.859	.001	55	view →
CCRCC	DFS	Tertile	III,IV	0.805	0.313	<.001	32	view →
COAD	DFS	Tertile	All	0.908	1.000	.038	12	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.303	.004	5	view →
UCEC	DFS	Tertile	All	0.956	0.788	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GOT1–PDAC (DFS)

Open the PDAC breakdown →